Ovarian Cancer: Maintenance

Ongoing treatment to keep ovarian cancer from coming back is now an option for many women.

SN Local - Explore expertise and community near you:

Maintenance: Therapy After the First Round of Treatment

A relatively new class of drugs called PARP Inhibitors is now an option for more patients as a way to keep ovarian cancer at bay

Maintenance

Ovarian Cancer - How You'll Be Monitored

Dr. Jonathan Berek
Stanford Medicine

Maintenance

The Drug Zejula Shows Important Long-Term, Progression-Free Survival Benefit For Patients With Advanced Ovarian Cancer

Dr. Rodrigo Leão Edelmuth
Hospital Israelita Albert Einstein

Maintenance

Studies Indicate The Drug Lynparza Extends Life of Patients with Ovarian Cancer

Dr. Rodrigo Leão Edelmuth
Hospital Israelita Albert Einstein

Dr. Michael Birrer

UAB Comprehensive Cancer Center

Treatment

Stimulating the Immune System to Help Control Ovarian Cancer-- Understanding Atezolizumab

Dr. Oliver Dorigo
Stanford University Medical Center

Maintenance: Therapy After the First Round of Treatment

A relatively new class of drugs called PARP Inhibitors is now an option for more patients as a way to keep ovarian cancer at bay

Maintenance: PARP Inhibitors as a Maintenance Tool

Maintenance

Should PARP Inhibitors be Given to All Patients?

Dr. Ritu Salani
UCLA Health

Maintenance

Studies Indicate The Drug Lynparza Extends Life of Patients with Ovarian Cancer

Dr. Rodrigo Leão Edelmuth
Hospital Israelita Albert Einstein

Maintenance

Side Effects of PARP Inhibitors

Dr. Ursula Matulonis
Dana-Farber Cancer Institute

Maintenance

PARP Inhibitors: Leading Experts Say The Fatigue You Get From Therapy is Often Worth The Benefit

Dr. Rebecca Arend
University of Alabama-Birmingham

Maintenance

PARP Inhibitors -- Advancing Ovarian Cancer Treatment

Dr. Michael Birrer
UAB Comprehensive Cancer Center

Maintenance

Evaluating Bevacizumab and PARP Inhibitors as Important Treatment Options

Dr. Michael Birrer
UAB Comprehensive Cancer Center

Maintenance

Should PARP Inhibitors be Given to All Patients?

Dr. Ritu Salani
UCLA Health

Maintenance

Studies Indicate The Drug Lynparza Extends Life of Patients with Ovarian Cancer

Dr. Rodrigo Leão Edelmuth
Hospital Israelita Albert Einstein

Maintenance

Side Effects of PARP Inhibitors

Dr. Ursula Matulonis
Dana-Farber Cancer Institute

Maintenance

PARP Inhibitors: Leading Experts Say The Fatigue You Get From Therapy is Often Worth The Benefit

Dr. Rebecca Arend
University of Alabama-Birmingham

Maintenance

PARP Inhibitors -- Advancing Ovarian Cancer Treatment

Dr. Michael Birrer
UAB Comprehensive Cancer Center

Maintenance

Evaluating Bevacizumab and PARP Inhibitors as Important Treatment Options

Dr. Michael Birrer
UAB Comprehensive Cancer Center

Maintenance: Deciding Whether PARP Inhibitors Are For You

Maintenance

Differences Between Types of PARP Inhibitors

Dr. Oliver Dorigo
Stanford University Medical Center

Maintenance

Recent Advances in Ovarian Cancer Treatment Give Hope

Dr. Ursula Matulonis
Dana-Farber Cancer Institute

Maintenance

An Extraordinary New Treatment Option for Ovarian Cancer: PARP Inhibitors

Dr. Jose Alejandro Rauh-Hain
MD Anderson Cancer Center

Maintenance: Deciding Whether PARP Inhibitors Are For You

Maintenance: Understanding Avastin (Bevacizumab)

Maintenance

An Ovarian Cancer Drug That Cuts Tumor Growth

Dr. Oliver Dorigo
Stanford University Medical Center

Maintenance

A Targeted Ovarian Cancer Treatment-- The Role of Avastin (Bevacizumab)

Dr. Beth Karlan
UCLA Medical Center

Maintenance

New PARP Inhibitor Combination Drug Approval for Ovarian Cancer Maintenance

Dr. Lynn Parker
Norton Cancer Institute

Maintenance

Should Your Treatment Also Include Bevacizumab, A Drug To Reduce Tumor Blood Flow?

Dr. Leslie Boyd
NYU Langone Health

Maintenance: Understanding Avastin (Bevacizumab)

SN Local - Explore Ovarian Cancer expertise and community near you: